



Index

Note: Page numbers of article titles are in **boldface** type.

A

- Aggression. See also *Violence*.
of psychotic patient,
nonpharmacologic management
of, 239–242
behavioral, 240–241
restraint, 241–244
seclusion, 241–244
treatment setting in,
239–230
pharmacologic management of,
242–251
- Amisulpride, in acute schizophrenia, versus
conventional antipsychotics, 147
versus haloperidol, 147
versus placebo, 143–144
in schizophrenia, for maintenance
treatment, 150
for negative symptoms, 152
- Antipsychotics. See also *Atypical
antipsychotics*.
history of, 191–192
in schizophrenia, acute phase, 217
comorbid with substance abuse,
122
late-onset, 106–108
time to remission with, 221
time to response with, 221
weight gain, diabetes, dyslipidemia
triad with, 165–175
- Arachadonic acid (AA). See *Essential
polyunsaturated fatty acids (EPUFAs)*.
- Assertive community training (ACT), for
patients with schizophrenia,
206–207
- Association studies, in schizophrenia, 50–51
catechol-*O*-methyltransferase
and, 51–52
classic markers in, 51
genes in neurodevelopmental
process and, 52
interpretation of, 52
serotonergic neurotransmission
and, 51

- Attention, in schizophrenia, 29
sustained, in schizophrenia, 33
- Atypical antipsychotics. See also
Antipsychotics.
in bipolar disorder, 9
in schizophrenia, 9
acute phase, 216–217
adverse effects of, dyslipidemias,
170–173
glucose metabolism
abnormalities,
169–170
hyperprolactinemia,
178–181
Q-T segment prolongation,
175–178
sexual, 181–184
weight gain, 165–169
for cognitive deficits, 34–36
late-onset, 108–111
mechanism of action of, on
cognitive deficits, 35–36
in substance abuse–schizophrenia
comorbidity, 122

B

- Benzodiazepines, for aggressive patient with
schizophrenia, 250
- Beta-blockers, for aggressive patient with
schizophrenia, 250
- Bipolar disorder, comparison with
schizophrenia, 2–10, 14
causes of, 6
characterization in, 3–4
cognitive performance in, 3
demographics in, 4–5
epidemiology in, 5–6
neuropathology in, 6–7
overlapping issues in, 9–10
pathophysiology in, 10
treatment response in, 8–9
- Boundaries, of schizophrenia, **1–24**
- Brain, neuropathology of, in schizophrenia
and bipolar disorder, 6–8

C

- Care pathway, quality care and, 222–223
- Catechol-O-methyltransferase, in schizophrenia, gene coding for, 51–52, 115
- Chromosomal abnormalities, in schizophrenia, 52–53
- Cigarette smoking, in schizophrenia, 126
- Clozapine, and smoking cessation, 126
for aggressive patient with schizophrenia, 247–248
in schizophrenia, for cognitive deficits, 34–36
late-onset, 108–109
refractory to treatment, 156, 158, 192
suicide reduction and, 124
triglyceride level increase with, 171
- Cognitive behavioral therapy, in schizophrenia, for obsessive-compulsive symptoms, 120
with pharmacotherapy, in schizophrenia, coping strategy enhancement in, 197–198
for negative symptoms, 198–199
for residual symptoms, 197
- Cognitive deficits, in schizophrenia, antipsychotic therapies for, 34–36
functional consequences of, 31–34
- Cognitive function, characterization of, 25
in schizophrenia, **25–40**
attention and information processing and, 29
contemporary understanding, 26–27
correlation with functional outcome, 32–33
executive function and, 28–29
historical perspective, 26
impaired, 31–32
learning and memory and, 30–31
rehabilitation outcome and, 33–34
specific deficits in, 27–31
working memory and, 27–28
- Cognitive remediation, for schizophrenia, 203–204
- Command hallucinations, violence and, 235
- Comorbidity, in schizophrenia, **115–139**
depressive disorders, 116–118
detection and management of, **115–139**

- medical, 125–130
obsessive-compulsive symptoms, 118–120
psychiatric, 116–124
substance abuse, 120–123
suicide, 123–124

- Consent to treatment, capacity for, in aggressive patient with schizophrenia, 251–252

D

- Delusions, violence and, 235–236
- Dementia praecox*, 104–105
schizophrenia and, 1–4
- Depressive disorders, in schizophrenia, 116–117
detection of, 117–118
management of, 118
prognostic significance of, 117
- Diabetes, atypical antipsychotic-related, 170
type 2, antipsychotic medication-related, in schizophrenia, 128–130
- Disulfiram, in substance abuse–schizophrenia comorbidity, 123
- Docosahexaenoic acid (DHA). See *Essential polyunsaturated fatty acids (EPUFAs)*.
- Dyslipidemias, atypical antipsychotic-related, 170–173

E

- Environment, genetic susceptibility and, in schizophrenia, 5
- Essential polyunsaturated fatty acids (EPUFAs), antipsychotic medication and, 86
in schizophrenia, brain phospholipids in, functional organization of, 87–89
sources and metabolic pathways of, 88, 90
in augmentation of antipsychotic therapy, 97
membrane phospholipids in, and neurodevelopment, 93
and signal transduction, 93–94
breakdown of, 91–92
metabolism of, 90–91
antipsychotic treatment effects on, 92–93

- dysregulation of, 94–97
 - synthesis of, 90–91
 - supplementation of, 94–96
 - with antioxidants, 96
- Evidence, transfer into clinical practice, 213–214
- Evidence-based treatment, in schizophrenia, 215–216
- Executive function, in schizophrenia, 28–29, 32
- Exercise and diet, of person with schizophrenia, 127
- Expressed emotion, by family of person with schizophrenia, 199–200, 278

F

-
- Family treatment, in schizophrenia, for relapse reduction, 199–201

G

-
- Genetics, and vulnerability to schizophrenia, 5
- of schizophrenia, **41–63**
- adoption studies in, 45–46
 - comorbidity and, 115–116
 - family studies in, 42–43
 - genetic epidemiology in, 42–46
 - mode of inheritance in, 46–48
 - counseling and predictive testing in, 55–56
 - genetic imprinting and, 48
 - heterogenous vs. unitary, 47–48
 - liability/threshold model and, 46–47
 - phenotype definition in, 54–55
 - molecular studies in, 48–54
 - association, 50–52
 - chromosomal abnormalities, 52–53
 - linkage, 48–50
 - trinucleotide repeats, 53–54
 - twin studies in, 43–45
- Glucose metabolism, with atypical antipsychotics, 169–170

H

-
- Head trauma, violence and, 235
- Hepatitis, risk for, in patient with schizophrenia, 126–127

- HIV infection, risk for, in patient with schizophrenia, 126–127
- Hyperlipidemia, antipsychotic medication-related, in schizophrenia, 128–130
- with atypical antipsychotics, 170–173
- Hyperprolactinemia, atypical antipsychotic-related, 178–180

I

-
- Information processing, in schizophrenia, 29

K

-
- Knowledge, transfer into clinical practice, time to, 214

L

-
- Learning and memory, in schizophrenia, 30–31

- Linkage studies, description of, 48–49
- in schizophrenia, classic markers in, 49–50
 - criticisms of, 49
 - replication to chromosomal regions and, 50

M

-
- Medication noncompliance, violent behavior and, 234
- Membrane phospholipids. See also *Phospholipids*.
- in schizophrenia, contents of, 88–89
 - dysregulation of, **85–102**
 - EPUFAs in augmentation of antipsychotics, 97
 - supplementation of combination EPUFAs and antioxidants, 96–97
 - supplementation of EPUFAs and, 94–96
 - therapeutic implications, 94–97
 - essential fatty acids in, 90
 - fatty acids and, functional organization of, 87–89
 - source and metabolic pathways of, 87–88
 - metabolism of, 87–88
 - neurodevelopment and, 93
 - signal transduction and, 93–94
- Memory, and learning, in schizophrenia, 30–31

- Memory (*continued*)
 in schizophrenia, episodic, 32
 working, 33
- Mental retardation, violence and, 235
- Metabolic syndrome, with atypical antipsychotics, 173–174
- Minimum effective dose, in schizophrenia, 220

N

- Naltrexone, for substance abuse–schizophrenia comorbidity, 123
- National Alliance for the Mentally Ill (NAMI), on criminalization of people with mental illness, 263–265
- Neuropathology, of brain, in schizophrenia and bipolar disorder, 6–8

O

- Obsessive-compulsive disorder
 overlap with schizophrenia, neurocognitive, 11
 pathophysiologic, 11
 phenomenologic, 10–11
 treatment and, 11–12
- Obsessive-compulsive symptoms, in schizophrenia, antipsychotics for, 119–120
 cognitive behavioral therapy for, 120
 detection of, 119
 prognostic significance of, 118–119
- Olanzapine, comparison studies with conventional antipsychotics, meta-analysis of, 151
 for aggressive patient with schizophrenia, 249
 in acute schizophrenia, intramuscular administration of, 149
 versus haloperidol, 146
 versus placebo, 142–143
 in schizophrenia, economic outcomes with, 154–155
 first-episode, 155
 for cognitive deficits, 34–36
 for cognitive symptoms, 153
 for depressive symptoms, 153
 for maintenance treatment, 150
 for negative symptoms, 152
 late-onset, 110
 quality of life with, 155
 refractory to treatment, 156–157

triglyceride level increase with, 171–172

- Outpatient commitment, benefits of, 259
 effectiveness of, 259–261
 judicially mandated, 259
 versus coerced community treatment, 258–259

P

- Paraphrenia*, 103
- Personal therapy, with pharmacotherapy, in schizophrenia, 196–197
- Pharmacotherapy, in schizophrenia, adverse effects of, **165–190**
 new and evolving, **141–163**
 synergy with psychosocial therapies, **191–211**
- Phenotype, in schizophrenia
- Phospholipids. See also *Membrane phospholipids*.
 in schizophrenia, altered synthesis of, EPUFAs in, 90–91
 breakdown of, 91
 by free radicals, 92
 by phospholipases, 91–92
 metabolism of, 93
 antipsychotic treatment effects on, 92–93
- Posttraumatic stress disorder (PTSD), in caregiver, of person with schizophrenia, 283–284
- Psychosocial treatment(s), with pharmacotherapy, in schizophrenia, **191–211**
 assertive community training, 206–207
 cognitive behavioral therapy, 197–199
 cognitive remediation, 203–204
 family treatment, 199–201
 for deficit symptoms, 193
 for noncompliance, 194
 for relapse prevention, 194–195
 personal therapy, 196–197
 psychodynamic psychotherapy, 195–196
 social skills training, 193, 201–203
 supported employment, 204–206
- Psychotherapy, with pharmacotherapy, in schizophrenia, 195–196

Q

- Q-T segment prolongation, with atypical antipsychotics, 175–176
 risk for, management of, 176, 178
- Quality care, for schizophrenic patients, **213–230**
 evidence-based treatment in, 215–216
 health economy and, 214
 in acute phase, 216–219
 in relapse prevention, 219–221
 treatment durations in, 221–222
 in daily practice, knowledge and evidence in, 213–214
- Quality management, 223–224
 in psychiatry, 223–224
 Psychiatry Quality Measurement program in, 224–226
 benefits of, 226–227
 data for, 225–226
 flexibility of, 226
- Quetiapine, adverse effects with, Q-T segment prolongation, 177–178
 comparison studies with conventional antipsychotics, meta-analysis of, 151
 for aggressive patient with schizophrenia, 249–250
 in acute schizophrenia, versus conventional antipsychotics, 147
 versus haloperidol, 146
 versus placebo, 142–143
 in schizophrenia, for cognitive deficits, 34–36
 for cognitive symptoms, 153
 for depressive symptoms, 154
 late-onset, 110–111
 refractory to treatment, 157–158
- R**
- Restraint, of hostile psychotic patient, 242
 best practices for, 243
 federal directions and standards for, 244
- Right to refuse treatment. See also *Treatment refusal*.
 history of, 253
- Risperidone, in acute schizophrenia, versus amisulpride, 148–149
 versus olanzapine, 148
- Risperidone, adverse effects with, hyperprolactinemia, 178–179
 Q-T segment prolongation, 177

- comparison studies with conventional antipsychotics, meta-analysis of, 150–151
- for aggressive patient with schizophrenia, 248–249
- in acute schizophrenia, versus conventional antipsychotics, 147
 versus haloperidol, 145–146
 versus placebo, 142
- in schizophrenia, first-episode, 155
 for cognitive deficits, 34–36
 for cognitive symptoms, 152–153
 for depressive symptoms, 153
 for hostility, 154
 for maintenance treatment, 149
 for negative symptoms, 152
 late-onset, 109–110
 refractory to treatment, 155–158

S

- Schizoaffective disorder, as overlap between schizophrenia and bipolar disorder, 10
 familial transmission of, 5
- Schizophrenia
 acute phase, antipsychotics in, 216–217
 augmentation of, 218–219
 nonresponse and options for, 217–218
 switching of, 218
 combination therapy in comorbidity, 219
 quality care in, 216–219
 adverse drug effects in, **165–190**
 aggression in, pharmacologic management of, 242–251
 adjunctive agents in, 245, 250–251
 atypical antipsychotics, 247–250
 depot preparations, 247
 drug choice for, 245–246
 Expert Consensus Guidelines 1999 for, 242–245
 typical antipsychotics, 246–247
 antipsychotics in, dosage of, 217
 selection of, 216–217
 as metabolic disorder, 85–86
 atypical antipsychotics in, 142–158
 acute symptoms, comparisons of, 148–149
 intramuscular administration, 149

Schizophrenia (*continued*)

- versus conventional anti-psychotics, 145, 147
 - versus haldol, 145–147
 - versus placebo, 142–144
- for acute symptoms, 142–149
- for cognitive symptoms, 152–153
- for depressive symptoms, 153–154
- for excitement or hostility, 154
- for negative symptoms, 152
- in first-episode, 155
- in maintenance treatment, 149–150
- in refractory schizophrenia, 155–158
- meta-analyses of random-controlled trials of, 150–151
- pharmacoeconomic studies of, 154
- quality of life and, 155
- boundaries of, **1–24**
- care pathways in, early intervention services, 76–77
- illness recognition in, 75–76
- cognitive function in, **25–40**
- comorbidity in, **115–139**
 - medical, 125–130
 - antipsychotic medication side effects, 127
 - hyperprolactinemia, 128
 - lifestyle factors in, 125–127
 - weight gain, diabetes, hyperlipidemia in, 128–130
 - psychiatric, 116–124
- comparison with bipolar disorder, 2–10
- comparison with obsessive-compulsive disorder, 1, 10–12, 14
- early intervention in, **65–83**
 - drive for, 66
 - early detection and, 74
 - issues in, appropriate treatment, 72–73
 - assessment of effectiveness, 74
 - false-positive identification rate, 74–75
 - physical and emotional side effects, 74
- outcome and duration of untreated psychosis, 66–67
 - evidence for and against, 67–69
- preventive, 69–70
- prodromal detection and, 70
 - studies of, 70–72
- early-onset, comparison with late-onset, 103–104
 - comparison with midlife-onset, 104
 - conventional neuroleptics in, 107–108
- genetics of, **41–63**
- historical perspective on, 1–3
- impact on family, 276–277
 - acute and posttraumatic stress disorder and caregiving, 283–284
 - guilt and grieving, 279
 - healing and, 284–290
 - reaction patterns and, adversary, 281
 - bystander, 280–281
 - custodian, 280
 - relationship patterns of siblings, 281–283
 - siblings outcomes, 279
 - stigmatization of family and patient, 277–279
- intervention in, timing and opportunities for, **65–83**
- late-onset, **103–113**
 - antipsychotics in, 105–106
 - atypical antipsychotics in, 108–111
 - conventional neuroleptics in, 106–107
 - course of disease in, 104–105
 - early-onset comparison with, 103–104
- maintenance treatment of, 222
- membrane phospholipid dysregulation in, **85–102**
- pharmacotherapy for, adverse effects of, **165–190**
 - new and evolving, **141–163**
 - with psychosocial therapies, **191–211**
- public health policy and, **273–294**
 - and planning for future care, urgent need for, 275–276
 - community development and support and, 290
 - family support and, 284–285
 - financial planning, 285–286
 - health services and, 289
 - housing and, 288–289
 - human resources support of family members, 289–290
 - human services policy environment, 286–287
 - intersectoral collaborations and effective interventions, 287–288

- pharmaceutical accessibility and, 287
 - work and, 288
 - quality care and, **213–230**
 - refractory, atypical antipsychotics for, 155–158
 - clozapine in, 192
 - relapse in, maintenance treatment and, 220
 - prevention of, 219–220
 - psychoeducation and, 220–221
 - rates of, 219
 - schizophrenia spectrum disorders and, 1, 12–14
 - stigma and public health policy for, **273–294**
 - violent patient with, **231–272**
- Schizophrenia spectrum disorders (SPDs), 1, 12–14
- comparison with schizophrenia,
 - genetic linkage in, 12–13
 - morphometric similarities in, 12–13
 - schizophreniform disorder and, 13–14
- Schizophrenic spectrum, and schizophrenia, 1–2, 14
- Schizophreniform disorder, and
- schizophrenia, 1, 14
 - schizophrenia and, 13–14
 - schizophrenia spectrum and, 13
- Schizotypal personality, and schizophrenia, 1, 14
- Seclusion, of hostile psychotic patient, 241
 - best practices for, 243
 - federal directions and standards for, 244
- Sertindole, in acute schizophrenia, versus haloperidol, 147
 - versus placebo, 143–144
- in schizophreia, for maintenance treatment, 150
- Sexual side effects, of conventional and atypical antipsychotics, 181–182
 - ejaculatory dysfunction, 182–183
 - erectile dysfunction, 182–183
 - fertility and pregnancy, 183–184
 - gender and, 182
 - priapism, 183
- Skills training
 - in schizophrenia, 31–32
 - assertive community training, 206–207
 - motor, 201–202
 - psychosocial, 201–203
- Smoking cessation, in persons with schizophrenia, 126
- Social skills training, cognitive remediation model, 201–202
 - motor skills model, 201–202
- social problem-solving model, 201, 203
- with pharmacotherapy, for schizophrenia, 201–203
- Stigma, and public health policy, for schizophrenia, **273–294**
- Substance abuse, in schizophrenia,
 - complications from, 120–121
 - detection of, 121
 - gender and, 120
 - neurobiologic theory for, 121
 - pharmacotherapy for, 122–123
 - self-medication hypothesis for, 121
 - violent behavior and, 234
- Substance use disorders, in schizophrenia, 116
- Suicide, schizophrenia and, detection of suicidal ideation in, 124
 - psychoeducation and medication compliance and, 124
 - psychopharmacologic interventions for, 124
 - risk factors for, 123–124
- Supported employment, in schizophrenia, 204–206
 - common elements of, 205
 - interpersonal placement and, 205–206
 - versus vocational rehabilitation, 205
-
- T**
- Treatment refusal. See also *Right to refuse treatment*.
- by aggressive patient with schizophrenia, duty to protect, 262–263
 - liability and documentation of, 261–262
 - psychiatric advance directives and, 257–258
- capacity to consent to treatment and, 251–252
- legal models for, incompetence component of commitment procedure, 253–254
- rights-driven, 253
 - treatment-driven, 253
- management of, accomodation, 256

Treatment refusal (*continued*)
 coercion and persuasion in,
 256–257
 consultation, 256
 negotiation, 256
 outpatient commitment, 258–261
 types of, illness-based, 255
 physician-patient relationship in,
 254–255
 religion-based, 255
 treatment-based, 255

V

Valproate, for aggressive patient with
 schizophrenia, 250

Velocardiofacial syndrome (VCFS), in
 bipolar disorder, 115
 in schizophrenia, 115
 relationship to schizophrenia, 53

Victimization, of mentally ill family
 member, 283–284

Violence. See also *Aggression*.
 advocacy and political efforts to
 reduce, 263–265
 and general population, 232–233
 Crisis Intervention Team model, police
 training for, 263, 265
 in mental illness, epidemiology of,
 232–236
 risk factors for, 233–236
 inpatient, 236–237
 in patients with schizophrenia. See also
Right to refuse treatment;
Treatment refusal.
 forced medication and right to
 refuse treatment, 251–263

of psychotic patient, treatment issues
 in, **231–272**
 outpatient, 258–261
 risk assessment of, in mentally ill
 person, 237–239

threat of, 238–239

W

Weight gain, antipsychotic medication-
 related, in schizophrenia, 128–130
 with atypical antipsychotics, 165–169
 in adolescents, 167
 predictors of, 167
 psychopharmacology of, 167–169
 5HT_{2c} antagonism and, 168
 leptin in, 168–169
 time course of progression in,
 166–167

Weight gain, diabetes, dyslipidemia triad,
 with atypical antipsychotics, 165–173
 management of, 173–175

Weight loss agents, for obesity, atypical
 antipsychotic-related, 174–175

Working memory, in schizophrenia, 27–28

Z

Ziprasidone, comparison studies with
 conventional antipsychotics, meta-
 analysis of, 151
 for aggressive patient with
 schizophrenia, 250
 in acute schizophrenia, intramuscular
 administration of, 149
 versus haloperidol, 146
 versus placebo, 143–144